Novartis unveiled today new data on its promising pipeline amid plans for multiple new product approvals and launches over the next two years. Many of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.
Positive opinion for Revlimid The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Revlimid (lenalidomide), from Celgene Europe, for the treatment of multiple myeloma. EMEA review began on 29 March 2006, with an active review time of 199 days. The active substance of Revlimid, lenalidomide, has a chemical structure that resembles that of thalidomide.